Evidence map›Paper›PMID 40629053›Full record

ArticleThe Journal of antibiotics2025

Griseolutein T from Streptomyces seoulensis, newly identified via combined-culture with Tsukamurella pulmonis, as an efficacious therapeutic agent against multidrug-resistant bacteria.

Sung-Jin Kawai, Shumpei Asamizu, Hiroaki Suzuki, Hiroyasu Onaka, Yoshichika Arakawa, Kouji Kimura, Makoto Ojika

Abstract read
In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sung-Jin Kawai *New Field Pioneering Division, Toyota Boshoku Corporation, Kariya, Aichi, Japan.
Shumpei Asamizu *Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan. shumpei.asamizu@port.kobe-u.ac.jp.ORCID 0000-0002-7178-5410
Hiroaki SuzukiNew Field Pioneering Division, Toyota Boshoku Corporation, Kariya, Aichi, Japan.
Hiroyasu OnakaGraduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-4536-1881
Yoshichika ArakawaGraduate School of Medicine, Nagoya University, Nagoya, Japan.
Kouji KimuraGraduate School of Medicine, Nagoya University, Nagoya, Japan.
Makoto OjikaGraduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial interactions can affect the production of secondary metabolites and, therefore, provide a promising approach to exploring new microbial compounds. In this study, we screened actinomycetes isolated from Hegura Island, Ishikawa Prefecture, Japan, to discover new antibiotics through combined-culture with Tsukamurella pulmonis TP-B0596. Three new phenazine-class antibiotics, griseoluteins T (1), C (2), and D (3), along with two known related metabolites, griseoluteic acid (4) and griseolutein A (5), were detected in both mono- and combined-cultures of Streptomyces seoulensis HEK131 with T. pulmonis at different production levels. Detailed spectroscopic analysis revealed that 1 contained a dihydrophenazine core, and was converted to 5 by accepting oxidation spontaneously. 1, containing a dihydrophenazine group, was relatively unstable under oxidative conditions, and the addition of ascorbate was required during the isolation of the compound. 2 and 3 were found to be cysteine-adducts analogous to 4, and their productivity was increased in the combined-culture. We further assessed the antibacterial activities of 1 against clinically significant Gram-positive pathogenic bacteria, including 30 methicillin-resistant Staphylococcus aureus (MRSA), 27 vancomycin-resistant Enterococci (VRE), and 17 Clostridioides difficile. Notably, 1 was found to possess higher antibacterial activity against these microorganisms than several clinically important antibiotics, while displaying lower cytotoxicity against HeLa-S3 cells.

Indexed as

ActinobacteriaAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialPhenazinesStreptomycesHeLa CellsHumansJapanMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsAnti-Bacterial AgentsPhenazines

Identifiers

PMID40629053
PMCPMC12380601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.